Search Results - "Berger, Melvin"

Role of anti-receptor autoantibodies in pathophysiology of scleroderma by Berger, Melvin, Steen, Virginia D.

“…The pathophysiology of SSc-mediated organ damage is complex and not well understood. Hallmarks of the disease include skin thickening, vasculopathy and…”
Get full text

Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation by Ueda, Masumi, Berger, Melvin, Gale, Robert Peter, Lazarus, Hillard M.

“…Immunoglobulins are used to prevent or reduce infection risk in primary immune deficiencies and in settings which exploit its anti-inflammatory and…”
Get full text

Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency by Berger, Melvin, MD, PhD

“…During the last 2 decades, the continued development and the large-scale production of polyclonal immune serum globulin (ISG) preparations with improved safety…”
Get full text

Adverse Effects of IgG Therapy by Berger, Melvin, MD, PhD

“…IgG is widely used for patients with immune deficiencies and in a broad range of autoimmune and inflammatory disorders. Up to 40% of intravenous infusions of…”
Get full text

Subcutaneous Administration of IgG by Berger, Melvin, MD, PhD

“…The availability of IgG preparations that could be administered safely by the intravenous route was finally achieved in the early to mid-1980s. Intravenous…”
Get full text

Bioavailability of IgG Administered by the Subcutaneous Route by Berger, Melvin, Jolles, Stephen, Orange, Jordan S., Sleasman, John W.

“…Purpose US licensing studies of subcutaneous IgG (SCIG) calculate dose adjustments necessary to achieve area under the curve (AUC) of serum IgG vs. time on…”
Get full text

Hereditary angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database by Farkas, Henriette, Levy, Donald, Supina, Dylan, Berger, Melvin, Prusty, Subhransu, Fridman, Moshe

“…Abstract In this letter to the editor, we present results of claims data analysis. This claims data analysis supports a hypothesis that in patients with…”
Get full text

Efficient Utilization of IgG for Antibody Replacement Therapy by Berger, Melvin, MD, PhD

“…[...]when one looks at the curve for IgG administered as an intravenous (IV) bolus once every few weeks, it is equally obvious that the trough level is the…”
Get full text

Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells by Saadane, Aicha, Eastman, Jean, Berger, Melvin, Bonfield, Tracey L

“…Excessive secretion of IL-8 characterizes cystic fibrosis (CF). This has been attributed to excessive activation of epithelial cell I-κB Kinase and/or NFκB…”
Get full text

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously by Desai, Shilpa H., BS, MD, Chouksey, Akhil, MD, Poll, John, RN, Berger, Melvin, MD, PhD

“…Because each subject was exposed to the same IgG preparation by both routes, the subject's preference for one route versus the other should not have been…”
Get full text

Low IgG Trough Levels at the End of 4 Week Treatment Cycle Regardless of the Administration Route by Berger, Melvin, MD, PhD, FAAAAI, Hubsch, Alphonse P, Sidhu, Jagdev S., PhD, Rojavin, Mikhail, PhD

“…Rationale Antibody deficiency patients on intravenous IgG (IVIG) once 3-4-weeks often report 'wear-off', a feeling of decreased well-being and increased…”
Get full text

A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies by Berger, Melvin

“…Processes for the large-scale fractionation of human plasma using cold ethanol were initially developed by Edwin Cohn and his colleagues at Harvard to provide…”
Get full text

The role of inflammation in the pathophysiology of CF lung disease by Chmiel, James F, Berger, Melvin, Konstan, Michael W

“…Cystic fibrosis (CF) lung disease is characterized by a self-perpetuating cycle of airway obstruction, chronic bacterial infection, and vigorous inflammation…”
Get full text

Pharmacokinetic Modeling Predicts Different IgG Exposures Using Different IVIG-Scig Dose Conversion Factors In Patients With Primary Immune Deficiency by Sidhu, Jagdev S., Dr, Rojavin, Mikhail, Dr, Berger, Melvin, Dr, Bexton, Martin, Dr, Edelman, Jonathan M., Dr

Get full text

Immunologists' Attitudes On "Wear-off" Effects of IgG Replacement Therapy for Primary Immunodeficiency Disease (PIDD) Patients by Ballow, Mark, MD, FAAAAI, Bullinger, Ann, PharmD, Murphy, Elyse A., RN, Berger, Melvin, MD, PhD, FAAAAI

Get full text

Efficacy and Tolerability Of Privigen® In Clinical Practice by Dorsey, Morna J., Dr, Ho, Viet, Mabudian, Mohsen I., Dr, Soler-Palacín, Pere, Domínguez-Pinilla, Nerea, Hellmers, Robert W., Dr, Rishi, Radha Gandhi, Dr, Rishi, Rahul, Wong, Duane W., Dr, Rojavin, Mikhail, Dr, Hubsch, Alphonse, Dr, Berger, Melvin, Dr

Get full text

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy by Lieberman, Phillip, MD, Berger, Melvin, MD, PhD, FAAAAI

“…If the weekly SCIG dose is 25% of the previously monthly IV dose (in other words, the same total monthly dose), then the steady-state level is likely to be 12%…”
Get full text

Antibodies to vaccine antigens in pooled polyclonal human IgG products by Berger, Melvin

“…Immune‐deficient patients depend on the antibodies in pooled human immunoglobulin G (IgG) preparations to remain free from serious infections. The potency of…”
Get full text

Comprehensive Assessment of Serious Adverse Events Following Immunization by Health Care Providers by Williams, S. Elizabeth, MD, Edwards, Kathryn M., MD, Baxter, Roger P., MD, LaRussa, Philip S., MD, Halsey, Neal A., MD, Dekker, Cornelia L., MD, Vellozzi, Claudia, MD, MPH, Marchant, Colin D., MD, Donofrio, Peter D., MD, Reimschisel, Tyler E., MD, Berger, Melvin, MD, Gidudu, Jane F., MD, Klein, Nicola P., MD, PhD

Get full text

Functional IL-10 Deficiency in the Lung of Cystic Fibrosis (cftr-/-) and IL-10 Knockout Mice Causes Increased Expression and Function of B7 Costimulatory Molecules on Alveolar Macrophages by Soltys, Jindrich, Bonfield, Tracey, Chmiel, James, Berger, Melvin

“…Alveolar macrophages are poor APCs that only minimally express B7 costimulatory molecules. Because our previous data suggest that bronchial epithelial cells…”
Get full text